FMTX Forma Therapeutics Holdings, Inc. Stock Quote

FMTX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.97	Insider Own	0.70%	Shs Outstand	42.38M	Perf Week	-9.21%
Market Cap	1.32B	Forward P/E	-	EPS next Y	-3.67	Insider Trans	0.00%	Shs Float	40.36M	Perf Month	-18.21%
Income	-74.20M	PEG	-	EPS next Q	-0.77	Inst Own	83.90%	Short Float	14.10%	Perf Quarter	-32.92%
Sales	-	P/S	-	EPS this Y	-120.20%	Inst Trans	36.52%	Short Ratio	11.20	Perf Half Y	-49.66%
Book/sh	15.30	P/B	1.64	EPS next Y	-16.50%	ROA	-16.60%	Target Price	-	Perf Year	-
Cash/sh	12.10	P/C	2.08	EPS next 5Y	-	ROE	-19.40%	52W Range	22.51 - 56.33	Perf YTD	-27.94%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-55.35%	Beta	-
Dividend %	-	Quick Ratio	20.60	Sales past 5Y	-	Gross Margin	-	52W Low	11.73%	ATR	2.25
Employees	103	Current Ratio	20.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	36.02	Volatility	6.92% 9.05%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	53.80%	Profit Margin	-	Rel Volume	0.96	Prev Close	24.97
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 30 BMO	Payout	-	Avg Volume	508.07K	Price	25.15
Recom	1.50	SMA20	-9.48%	SMA50	-24.80%	SMA200	-36.00%	Volume	484,286	Change	0.72%

Mar-31-21

Reiterated

H.C. Wainwright

Buy

$53 → $55

Feb-17-21

Initiated

Oppenheimer

Outperform

$60

Sep-08-20

Initiated

H.C. Wainwright

Buy

$53

Jul-14-20

Initiated

SVB Leerink

Outperform

$54

Jul-14-20

Initiated

Jefferies

Buy

$54

Jul-14-20

Initiated

Credit Suisse

Outperform

$64

Mar-30-21 11:08AM	Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study Benzinga
07:20AM	Forma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business Update Business Wire
07:05AM	Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study Business Wire
06:15AM	Forma Therapeutics Holdings Inc to Host Earnings Call ACCESSWIRE
Mar-23-21 04:05PM	Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021 Business Wire -10.89%
Mar-03-21 08:50AM	Why Forma Therapeutics (FMTX) Might Surprise This Earnings Season Zacks -8.21%
Feb-17-21 07:05AM	Forma Therapeutics to Participate in Upcoming Investor Conferences Business Wire +7.53%
Jan-20-21 07:05AM	Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) Business Wire
Jan-11-21 07:05AM	Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones Business Wire
Jan-07-21 07:05AM	Forma Therapeutics Elects Renowned Doctor and Health Disparities Expert Selwyn M. Vickers, M.D., to Board of Directors Business Wire
Dec-19-20 03:11AM	How Much Of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Do Institutions Own? Simply Wall St.
Dec-15-20 04:35PM	Forma Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares Business Wire
Dec-10-20 10:53PM	Forma Therapeutics Announces Pricing of Public Offering Business Wire -10.92%
06:34PM	Is FMTX A Good Stock To Buy Now? Insider Monkey
Dec-08-20 04:15PM	Forma Therapeutics Launches Proposed Public Offering Business Wire +20.69%
Dec-07-20 04:30PM	Forma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting Supporting the Potential of its Novel Investigational PKR Activator, FT-4202, to Treat Sickle Cell Disease (SCD) Business Wire
Nov-12-20 07:05AM	Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Business Wire
Nov-10-20 07:05AM	Forma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease Business Wire
Nov-04-20 01:11PM	Forma Therapeutics Announces Four Oral and Poster Presentations on FT-4202 in Sickle Cell Disease at Upcoming 2020 ASH Virtual Annual Meeting Business Wire -10.27%
07:05AM	Forma Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Oct-26-20 07:05AM	Forma Therapeutics Announces Positive Top-line Olutasidenib Data From a Planned Interim Analysis of a Registrational Phase 2 Clinical Trial in Acute Myeloid Leukemia (AML) Business Wire
Sep-20-20 10:40AM	We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Can Afford To Drive Business Growth Simply Wall St.
Sep-15-20 07:05AM	Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions Business Wire
Sep-09-20 07:05AM	Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of Directors Business Wire
Aug-13-20 07:05AM	Forma Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update Business Wire
Jul-30-20 07:05AM	Forma Therapeutics Elects Distinguished Researcher and Physician Wayne A.I. Frederick, M.D., to Board of Directors Business Wire
Jul-02-20 07:30PM	Leaf Group, Forma Therapeutics See Activist Action Barrons.com
Jun-23-20 04:05PM	Forma Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares Business Wire
Jun-18-20 09:04PM	Forma Therapeutics Announces Pricing of Initial Public Offering Business Wire

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Potts Jeannette	See Remarks	Dec 30	Option Exercise	5.05	3,400	17,170	3,400	Jan 08 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience